98%
921
2 minutes
20
Noncovalent interactions, particularly chalcogen bonds (ChBs), have gained prominence in modern chemistry due to their tunability and directionality. We present a pioneering investigation of a d metal-involving ChB in triazolylidene Au(I) complexes. The crystal structures reveal the occurrence of intramolecular ChBs between Au(I) and chalcophene substituents positioned on the wingtip of triazolylidene ligands. The strength of these ChB interactions can be effectively modulated by altering the chalcophene moieties and ancillary ligands associated with Au(I). The neutral LAu(I)X complexes exhibit remarkable phosphorescence, with photoluminescence quantum yield (PLQY) reaching up to 70% in the solid state, which is attributed to their rigid structure with intramolecular ChB interactions between the Au and chalcogen atoms. Moreover, density functional theory (DFT) calculations were performed to obtain insights into the nature of the ChB interactions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/d4dt03508a | DOI Listing |
Acta Epileptol
September 2025
Department of Electronics Engineering, K. J. Somaiya School of Engineering (formerly K. J. Somaiya College of Engineering), Somaiya Vidyavihar University, Mumbai, 400077, Maharashtra, India.
Background: The detection of epileptic seizures is a crucial aspect of epilepsy care, requiring precision and reliability for effective diagnosis and treatment. Seizure detection plays a critical role in healthcare informatics, aiding in the timely diagnosis and management of epilepsy. The use of computational intelligence and optimization techniques has shown significant promise in improving the performance of automated seizure detection systems.
View Article and Find Full Text PDFChemistry
August 2025
College of Chemistry and Materials Science, Hebei Key Laboratory of Inorganic Nanomaterials, Hebei Normal University, Shijiazhuang, 050024, China.
Chalcogen bond (ChB) catalysts have recently garnered considerable attention in the field of organocatalysis owing to their advantages of nontoxicity, environmental sustainability, extensive applicability, affordability, and remarkable reactivity. In this work, the Se- and Te-based cationic hypervalent ChB catalysis on the bromolactonization reaction of N-Bromosuccinimide (NBS) with 4-pentenoic acid is investigated by high-level density functional theory (DFT) calculations. The ChB-catalyzed bromolactonization reaction has an intricate process involving bromine transfer, cyclization, and proton transfer.
View Article and Find Full Text PDFJ Hepatol
August 2025
Vir Biotechnology, Bellinzona, Switzerland. Electronic address:
Background & Aims: Effective immune targeting is likely essential for achieving functional cure of chronic hepatitis B (CHB). Tobevibart, a human monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg), neutralizes HBV and hepatitis delta virus (HDV). This study aimed to characterize effects of the engineered GAALIE Fc of tobevibart on HBV immune responses.
View Article and Find Full Text PDFJ Neural Eng
August 2025
Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences, 1068 Xueyuan Avenue Nanshan Xili, Shenzhen, Shenzhen, Guangdong, 518055, CHINA.
Objective: Epilepsy is a neurological disorder characterized by recurrent seizures, which present significant challenges in both diagnosis and treatment. Despite advances in seizure detection, existing methods often struggle with accurately capturing the complex and dynamic interactions between temporal, spatial, and spectral features of EEG signals. This leads to limitations in the detection accuracy and generalization across different datasets.
View Article and Find Full Text PDFAntibodies (Basel)
July 2025
Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Pompe disease is a rare autosomal-recessive neuromuscular disorder caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), leading to the pathological accumulation of glycogen and impaired autophagy. Enzyme replacement therapy (ERT) with recombinant human alpha-glucosidase (rhGAA) has been available since 2006, but may lead to the formation of anti-drug antibodies (ADAs) against the recombinant human enzyme, which, in turn, may adversely affect the response to ERT. Knowledge of the antigenic determinants of rhGAA involved in interaction with ADAs may facilitate the development of strategies to attenuate the anti-drug immune response in patients.
View Article and Find Full Text PDF